Small-molecular tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor-2 in the treatment of non-small cell lung cancer

  • Yin-Xian Wen

Abstract

Lung cancer is the leading cause of cancer-related death all around the world.Non-small cell lung cancer (NSCLC) accounts for almost 87% of all lung cancers. It has been well established that tumor angiogenesis is one of major mechanisms of tumor progression. Vascular endothelial growth factor receptor (VEGFR) signal pathway may be the dominant pathway involved in tumor angiogenesis, while the VEGFR-2 is now believed to the most important member of the VEGFR family

Published
Feb 7, 2015
How to Cite
WEN, Yin-Xian. Small-molecular tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor-2 in the treatment of non-small cell lung cancer. Open Journal of Medicine, [S.l.], v. 3, n. 1, feb. 2015. Available at: <http://imed.pub/ojs/index.php/ojmedicine/article/view/1030>. Date accessed: 24 aug. 2017.
Section
Articles

Keywords

Angiogenesis; VEGFR-2; non-small cell lung cancer; tyrosine kinase inhibitors; targeted therapy